Artiva Halts Therapy and Cuts 94% of Staff
Artiva Biotherapeutics is discontinuing its experimental cell therapy for autoimmune conditions and slashing its workforce by 94 percent following two patient deaths in a mid-stage clinical trial. The company will now evaluate strategic alternatives as shares slump 32 percent.
Xurve View
Insights:
Xurve View
Artiva Biotherapeutics will halt development of its lead cell therapy and cut its workforce by 94% following two patient deaths, sending shares plunging 32%. The sudden termination ends the clinical path for AlloNK after safety complications derailed the mid-stage trial. Investors face a total loss of momentum in the company's core pipeline as management evaluates strategic alternatives.
